Ichor and Janssen to collaborate to develop and commercialise immunotherapies for chronic Hepatitis B

Ichor Medical Systems has announced that it has entered into a product development collaboration and worldwide license agreement with Janssen Pharmaceuticals.

Under the agreement, which was facilitated by Johnson & Johnson Innovation, the parties will work together to develop and commercialize DNA-based vaccine products for the treatment of chronic hepatitis B using Ichor’s TriGrid™ electroporation technology for clinical administration.

Ichor will receive an upfront payment, R&D support, and development and sales milestone payments up to a potential total of approximately $85 million USD, as well as royalty payments on any future licensed product sales. Janssen will assume responsibility for certain development costs and all commercialization costs associated with the program, including manufacturing and distribution expense for Ichor’s TriGrid Delivery System.

Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). More than two billion people alive today have been infected with HBV. Presently, there are over 240 million people worldwide that carry the virus and remain chronically infected. Current treatments seldom eliminate the virus and are often associated with severe adverse reactions.

DNA vaccines are an emerging vaccine platform that are able to generate antigen-specific antibodies and T cells, the latter being crucial for long-term resolution of HBV infection. However, the efficacy of DNA vaccines delivered by conventional injection has been hindered by poor delivery efficiency, resulting in suboptimal immune responses in clinical trials. Electroporation is a potent delivery method that uses brief electrical pulses to transiently alter cell membranes, facilitating entry of DNA into cells.

Ichor’s TriGrid delivery system is the first integrated and fully automated device for electroporation-mediated DNA administration in humans

Ichor’s TriGrid delivery system, which is currently being tested in clinical trials in four continents, is the first integrated and fully automated device for electroporation-mediated DNA administration in humans. Previous clinical studies have shown the TriGrid to significantly enhance immune responses to the delivered vaccines compared to conventional injection, leading to positive clinical outcomes in diseased populations.

Robert Bernard, Ichor Founder and CEO, stated, “Janssen’s decision to couple our clinically validated TriGrid electroporation technology with their DNA vaccine for HBV is extraordinarily exciting for Ichor. Our scientists and engineers look forward to this opportunity to collaborate with Janssen in the development of immunotherapies for patients suffering from chronic hepatitis B infection.”

For more information about Ichor, please visit ichorms.com. For more on Janssen, please visit janssenpharmaceuticalsinc.com.